Edesa Biotech enters $5M securities purchase agreement with CEO; $1.54M immediate investment

Edesa Biotech, Inc.

CEO-affiliated entity invests $1,540,819 for 150 Series A-1 Preferred Shares ($10K stated value) and warrants at $3.445 conversion/exercise price.
Preferred shares convertible into 435,414 common shares; warrants cover 326,560 common shares (75% of conversion shares).
Up to $5M total investment possible; purchases over $2M require shareholder approval under Canadian law.
$10M revolving credit facility with same entity terminated; no funds drawn and no termination penalties.
Securities issued in private placement exempt from registration; subject to Canadian hold periods.

item 1.01 item 5.03 item 1.02 item 2.03 item 3.02 item 3.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Edesa Biotech, Inc.: Filed Amended Articles to amend rights, preferences, restrictions and other matters pertaining to the Preferred Shares (effective 2024-10-30).

Change: charter amendment
Effective: 2024-10-30

Exact text from the filing

On October 30, 2024, the Company filed Amended Articles to amend the rights, preferences, restrictions and other matters pertaining to the Preferred Shares.

View on SEC.gov

11 governance changes filed in the last 30 days. Browse all governance changes →

Edesa Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-005928

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.